سعر دولسيل إم 2/1000 مجم 20 قرص مغلف 2024

Dolcyl M film-coated tablets: glimepiride 2 mg + metformin 1000 mg; MUP; pack of 20.

• Treatment of type 2 diabetes mellitus when diet, physical exercise and weight reduction alone are not adequate.Population: Adults with type 2 diabetesMHRA / emc

• Hypoglycaemia (rare but may be severe); visual disturbances (transient); GI: nausea, vomiting, diarrhoea, abdominal pain (very rare); haematological disorders (rare, usually reversible); skin hypersensitivity; hepatic enzyme increase / rare hepatic failure.General active-ingredient information · MHRA / emc

• Hypersensitivity to glimepiride, other sulfonylureas or sulfonamides, or excipients; type 1 diabetes; diabetic coma; ketoacidosis; severe renal or hepatic impairment (switch to insulin required).General active-ingredient information · MHRA / emc

• Risk of hypoglycaemia especially with irregular meals, alcohol, renal/hepatic impairment, or interacting drugs. Regular blood/urine glucose and periodic hepatic and haematological monitoring required. Temporary switch to insulin may be needed in stress (infection, surgery). Caution in G6PD deficiency (haemolytic anaemia risk).General active-ingredient information · MHRA / emc

• CYP2C9 inhibitors (e.g. fluconazole) / inducers (e.g. rifampicin)MajorGlimepiride is metabolized by CYP2C9; inhibitors may potentiate hypoglycaemia (fluconazole ~2-fold AUC increase); inducers may weaken effect.MHRA / emc
• AlcoholModerateAlcohol may potentiate or weaken the hypoglycaemic action of glimepiride unpredictably.MHRA / emc

• Glimepiride should not be used during the whole pregnancy; switch to insulin as soon as pregnancy is planned or discovered. Abnormal blood glucose in pregnancy increases congenital abnormalities and perinatal mortality risk.General active-ingredient information · MHRA / emc
• Breast-feeding is advised against during glimepiride treatment (risk of hypoglycaemia in nursing infants; other sulfonylureas are excreted in human milk).General active-ingredient information · MHRA / emc

• Glimepiride: Sulfonylurea that lowers blood glucose mainly by stimulating insulin release from functioning pancreatic beta cells (US label).
• Metformin: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).